Financial performance: Q3 and nine-month Group revenue of €164.9 m and €465.0 m, respectively (Q3: €164.2 m, 9M: €477.4 m at CER); adj. Group EBITDA of -€1.6 m and -€44.3 m, respectively (Q3: -€1.7 m, 9M: -€39.1 m at
HAMBURG, Germany, Oct. 29, 2026 /PRNewswire/ -- Evotec SE (NASDAQ:EVO) (Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the first nine months 2026 and provide
Will lead Evotec's global scientific strategy and drive differentiation across its discovery and development services, technology platforms and proprietary innovationBrings more than 25 years of global experience in
Dr. Cord Dohrmann to step down as of September 30, 2026Search ongoing for a successorHAMBURG, Germany, Sept. 29, 2026 /PRNewswire/ -- Evotec SE (NASDAQ:EVO) (Frankfurt Prime Standard: EVT) today announced that Chief
First-in-human Phase 1 study initiated for investigational antibodies targeting orthopoxviruses developed under U.S. Department of War Accelerated Antibodies ProgramSupports development of countermeasures
Collaboration aims to validate Evotec's proprietary BiTco costimulatory CD2 bispecifics platform in combination with Plectonic's logic-gated DNA-protein immunotherapy technology LOGIBODY®BiTco designed to boost
Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's
Collaboration will support pharmacokinetic, pharmacodynamic, and bioanalytical studies for Niagen Bioscience’s lead investigational candidate for rare pediatric diseasesEvotec brings deep drug development expertise,
Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting
Navan (NASDAQ:NAVN), the global AI-powered business travel and expense platform, today announced
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
HAMBURG, Germany, July 13, 2026 /PRNewswire/ -- Evotec SE (NASDAQ:EVO) (Frankfurt Prime Standard: EVT) today announced
Expands Just – Evotec Biologics partner-enablement and technology licensing model for proprietary continuous manufacturing platformEnables deployment of continuous manufacturing platform in partner-owned facilities to
11.06.2026 / 15:30 CET/CESTThe issuer is solely responsible for the content of this announcement.
All agenda items adoptedDieter Weinand and Dr. Wolfgang Hofmann newly elected to the Supervisory BoardDieter Weinand
HAMBURG, DE / ACCESS Newswire / June 2, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Rui Wang as Executive Vice President, Head of Global In Silico and AI. Mr. Wang
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH, OR TO PERSONS IN ANY JURISDICTION TO WHOM, SUCH RELEASE,
Joint Evotec-Almirall team advances small molecule program to preclinical development significantly outperforming standard industry timelinesCollaboration leverages Evotec's end-to-end integrated AI/ML-driven R&D
